{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:13Z","timestamp":1772165893226,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We treated 260 patients with NSCLC and symptomatic bone metastasis. Thirty-seven patients harboring EGFR mutation were treated with gefitinib for more than 30\u00a0days and followed up for more than 3\u00a0months (GEF group). We performed a retrospective observational study by selecting 36 cases without EGFR-TKI treatment, at least 3\u00a0months of follow-up, and at least two radiological evaluations as the control group. We assessed the best overall radiological response, interval from treatment initiation to appearance of a radiological response, and the local response maintenance rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The best effect in the GEF group was 98% partial response or better, which was significantly higher than the 57% observed in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The GEF and control groups maintained 83% and 42% local response maintenance rates at one year, respectively (p\u2009&lt;\u20090.001). In the GEF with radiotherapy group, the local response maintenance rate was maintained at 92% at 1\u00a0year, while in the GEF without RT group, there was a decrease in the local response maintenance rate from 270\u00a0days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gefitinib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients. Combined gefitinib and radiotherapy provide long-lasting local control of bone metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-022-02226-1","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T09:04:18Z","timestamp":1672304658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis"],"prefix":"10.1186","volume":"22","author":[{"given":"Michihito","family":"Miyagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-3604","authenticated-orcid":false,"given":"Hirohisa","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Wasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"Suppl 5","key":"2226_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdq189","volume":"21","author":"G D\u2019Addario","year":"2010","unstructured":"D\u2019Addario G, Fr\u00fch M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):116\u20139.","journal-title":"Ann Oncol"},{"key":"2226_CR2","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s\u20139s.","journal-title":"Clin Cancer Res"},{"key":"2226_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165\u201376.","journal-title":"Cancer Treat Rev"},{"key":"2226_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","volume":"57","author":"A Tsuya","year":"2007","unstructured":"Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 2007;57:229\u201332.","journal-title":"Lung Cancer"},{"key":"2226_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/JTO.0b013e31819518fc","volume":"4","author":"H Al Husaini","year":"2009","unstructured":"Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA. Prevention and management of bone metastases in lung cancer: a review. J Thorac Oncol. 2009;4:251\u20139.","journal-title":"J Thorac Oncol"},{"key":"2226_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/JTO.0b013e31819518fc","volume":"4","author":"S Wu","year":"2009","unstructured":"Wu S, Pan Y, Mao Y, Chen Y, He Y. Current progress and mechanisms of bone metastasis in lung cancer: a narrative review. J Thorac Oncol. 2009;4:251\u20139.","journal-title":"J Thorac Oncol"},{"key":"2226_CR7","doi-asserted-by":"crossref","unstructured":"Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G. Textbook of Bone Metastses. John Wiley & Sons Ltd; 2005.","DOI":"10.1002\/0470011610"},{"issue":"Suppl","key":"2226_CR8","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(Suppl):1588\u201394.","journal-title":"Cancer"},{"key":"2226_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1758834014521110","volume":"6","author":"C D\u2019Antonio","year":"2014","unstructured":"D\u2019Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6:101\u201314.","journal-title":"Ther Adv Med Oncol"},{"key":"2226_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","volume":"466","author":"H Sugiura","year":"2008","unstructured":"Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 2008;466:729\u201336.","journal-title":"Clin Orthop Relat Res"},{"key":"2226_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839\u201344.","journal-title":"Clin Cancer Res"},{"key":"2226_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam SS, Yang JC-H, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation\u2013positive advanced non\u2013small-cell lung cancer. J Clin Oncol\u00a0 2018;36:841\u20139.","journal-title":"J Clin Oncol\u00a0"},{"key":"2226_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4184\/asj.2008.2.2.109","volume":"2","author":"M Zukawa","year":"2008","unstructured":"Zukawa M, Nakano M, Hirano N, Mizuhashi K, Kanamori M. The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -. Asian Spine J. 2008;2:109\u201313.","journal-title":"Asian Spine J"},{"key":"2226_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1620\/tjem.228.163","volume":"228","author":"M Hashisako","year":"2012","unstructured":"Hashisako M, Wakamatsu K, Ikegame S, Kumazoe H, Nagata N, Kajiki A. Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis. Tohoku J Exp Med. 2012;228:163\u20138.","journal-title":"Tohoku J Exp Med"},{"key":"2226_CR15","first-page":"319","volume":"34","author":"A Del Conte","year":"2014","unstructured":"Del Conte A, Minatel E, Schinella D, Baresic T, Basso SM, Lumachi F. Complete metabolic remission with gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer. Anticancer Res. 2014;34:319\u201322.","journal-title":"Anticancer Res"},{"key":"2226_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1269\/jrr.09096","volume":"51","author":"H Harada","year":"2010","unstructured":"Harada H, Katagiri H, Kamata M, et al. Radiological Response and Clinical Outcome in Patients withFemoral Bone metastases after Radiotherapy. J Radiat Res. 2010;51:131\u20136.","journal-title":"J Radiat Res"},{"key":"2226_CR17","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","volume":"22","author":"T Hamaoka","year":"2004","unstructured":"Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942\u201353.","journal-title":"J Clin Oncol"},{"key":"2226_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lungcan.2010.04.003","volume":"71","author":"J-M Sun","year":"2011","unstructured":"Sun J-M, Ahn JS, Lee S, et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer\u00a0 2011;71:89\u201393.","journal-title":"Lung Cancer\u00a0"},{"key":"2226_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00256-011-1253-9","volume":"41","author":"Y Yamashita","year":"2012","unstructured":"Yamashita Y, Aoki T, Hanagiri T, et al. Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response. Skelet Radiol. 2012;41:409\u201314.","journal-title":"Skelet Radiol"},{"key":"2226_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Nati Cancer Inst. 2005;97:339\u201346.","journal-title":"J Nati Cancer Inst"},{"key":"2226_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.","journal-title":"Lancet Oncol"},{"key":"2226_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1677\/erc.1.00956","volume":"12","author":"N Normanno","year":"2005","unstructured":"Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005;12:471\u201382.","journal-title":"Endocr Relat Cancer"},{"key":"2226_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature09870","volume":"471","author":"TG Bivona","year":"2011","unstructured":"Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011;471:523\u20136.","journal-title":"Nature"},{"key":"2226_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/CCO.0b013e32835d720b","volume":"25","author":"S Peters","year":"2013","unstructured":"Peters S, Meylan E. Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. Curr Opin Oncol. 2013;25:137\u201344.","journal-title":"Curr Opin Oncol"},{"key":"2226_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/sj.bjc.6605490","volume":"102","author":"X Lu","year":"2010","unstructured":"Lu X, Kang Y. Epidermal growth factor signalling and bone metastasis. Br J Cancer. 2010;102:457\u201361.","journal-title":"Br J Cancer"},{"key":"2226_CR26","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1101\/gad.1824809","volume":"23","author":"X Lu","year":"2009","unstructured":"Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23:1882\u201394.","journal-title":"Genes Dev"},{"key":"2226_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00776-014-0562-y","volume":"20","author":"Y Kishimoto","year":"2015","unstructured":"Kishimoto Y, Iwase T, Yano T, et al. Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings. J Orthop Sci. 2015;20:914\u20138.","journal-title":"J Orthop Sci"},{"key":"2226_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"2226_CR29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00256-007-0388-1","volume":"36","author":"CC Quattrocchi","year":"2007","unstructured":"Quattrocchi CC, Santini D, Dell\u2019aia P, et al. A prospective analysis of CT density measurements of bone metastases after treatment with zoledronic acid. Skelet Radiol\u00a0 2007;36:1121\u20137.","journal-title":"Skelet Radiol\u00a0"},{"issue":"48","key":"2226_CR30","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Mao C, Tang JL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985\u201393.","journal-title":"Oncotarget"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-02226-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T09:04:22Z","timestamp":1672304662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-02226-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-02226-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1500245\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study, which investigates past treatment by going back through medical records. In addition to being a study based on past medical information, most of the patients have already died because the study targets patients with bone metastases from lung cancer, and it is practically impossible to obtain the consent of each patient to participate in the study. We used the standard and best practices at the time of treatment, and we obtained written consent for every treatment.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Instead, we publish our research on our website and the hospital's bulletin board.The procedure of this study and the collection, analysis, and publication of the data were approved by the Shizuoka Cancer Center Review Board (ID 26-J109-26\u20131-3), and the requirement for written informed consent and the consent to participate was waived due to the retrospective design of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T. Takahashi received research funding and honoraria for a lecture from Astrazeneka K.K., H. Murakami received research funding and honoraria for a lecture from Astrazeneka K.K., Daiichi Sankyo, Novartis, and H. Harada received honoraria for a lecture from Astrazeneka K.K., Pfizer Japan Inc., Eli Lilly and Company, MSD K.K., and Brainlab AG. The other authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"491"}}